ReviewClinical, cosmetic and investigational dermatology2026
The Role of Dermocosmetics in Acne Management: Implications for Clinical Practice in Brazil.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne is a prevalent skin condition worldwide, affecting diverse populations, including Brazil. Although acne guidelines are well established for topical and/or systemic medications, recommendations regarding dermocosmetics, which have become increasingly important in acne management, remain limited. This review examines the role of dermocosmetics within acne treatment protocols and provides practical guidance for their integration into skincare routines alongside conventional therapies. Six dermatology experts conducted structured PubMed literature searches (2012-2024) and discussed the findings during expert meetings focused on acne management and dermocosmetics in the Brazilian context. Despite increasing evidence of benefit, the role of dermocosmetics remains underreported, with systemic treatments predominating. Acne pathophysiology is complex with four main pillars: hyperkeratinization of the pilosebaceous gland infundibulum, inflammation, overactivity of sebaceous glands, and microbiome imbalance in the context of an altered skin barrier. Advances in acne microbiome research highlight the importance of targeting dysbiosis, with new treatments exploring pre-, pro-, and postbiotics and bacteriophages. Dermocosmetics containing key active ingredients can address these multifactorial targets of acne, including excessive sebum production, hyperkeratinization, inflammation, and skin barrier and microbiome imbalance. They have been shown in clinical studies to be beneficial as monotherapy for mild cases, as maintenance therapy, or as adjuncts to acne medications. Due to their safety and tolerability profile, dermocosmetics are especially valuable for specific populations, such as pregnant women and prepubertal patients. Published evidence and expert clinical consensus support integrating dermocosmetics into daily routines to enhance acne control, patient adherence, and quality of life. Effective patient education on skincare regimens prevents treatment-related issues and optimizes outcomes. Incorporating dermocosmetics and improving patient education may further optimize these benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.